psoriasis
Phase 2b Trial: TAK-279 Improves Skin Clearance for Moderate to Severe Plaque Psoriasis
Results from a phase 2b trial indicate that the investigational drug TAK-279 (Takeda) significantly improved ...
MARCH 20, 2023
FDA Approves Sotyktu for Patients With Moderate to Severe Plaque Psoriasis
Deucravacitinib is indicated for adults with moderate to severe plaque psoriasis who are candidates for systemic ...
SEPTEMBER 13, 2022
FDA Approves First Steroid-Free Cream for Plaque Psoriasis
Vtama is an aryl hydrocarbon receptor agonist approved for adults with plaque psoriasis.
MAY 24, 2022
FDA Grants Second Indication for Skyrizi
Risankizumab-rzaa is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 ...
JANUARY 24, 2022
Study Links Psoriasis Therapy to Improved Heart Disease
Treating psoriasis with biologic drugs that target inflammation can reduce the early plaque buildup that leads to ...
FEBRUARY 14, 2019
Secukinumab Rx Improves Quality-of-Life Measurements as Early as 4 Weeks
Findings suggest that helping patients feel better through improved quality of life and ability to function ...
JANUARY 28, 2019
Psoriasis Severity Linked to Increased Risk for Death
The risk of death almost doubles for psoriasis patients, which have plaques on 10% or more of their body surface, ...
AUGUST 29, 2017
FDA Approves Siliq for Psoriasis
Psoriasis, an autoimmune disorder, occurs more commonly in patients with a family history of the disease, and most ...
FEBRUARY 15, 2017
FDA Approves Amjevita, a Biosimilar to Humira
The anti-inflammatory drug is the fourth biosimilar to be approved in the United States.
SEPTEMBER 27, 2016
